செலவு பயனுள்ள அடையாளம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2)
- Early and Cost-Effective Identification of Samples Potentially Containing the B.1.1.7 or Other Variants May Help Reduce Further Spread of Infection -
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) published a safety communication (the Communication ) that identifies the Company s Linea COVID-19 Assay Kit (the Assay Kit ) as one of only two tests marketed under the FDA s Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K. variant of SARS-CoV-2 (B.1.1.7). According to recent publications, the B.1.1.7 variant has been identified within the United States and may be associated with an increased risk of transmission of the virus that causes COVID-19. The identification of certain mutations can help identify samples that should be further ch ....

United States , Jamesa Hayward , Mike Munzer , Sciences Inc , Drug Administration , Company Assay Kit , Clinical Laboratory Improvement Amendments , Company Linea , Securities Exchange , York State Department Of Health , Cost Effective Identification , Samples Potentially Containing , Polymerase Chain Reaction , Use Authorization , Assay Kit , Pooled Surveillance , Russell Microcap , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , New York State Department , Emergency Use Authorization , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , அறிவியல் இன்க் , நிறுவனம் மதிப்பீடு கிட் ,